Role of surgical resection for patients with recurrent or metastatic gastrointestinal stromal tumors: A systematic review and meta-analysis
| Autor: | Yuan Yin, Chaoyong Shen, Zhaolun Cai, Sumin Tang, Xiaonan Yin, Bo Zhang, Zhi-Xin Chen |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Surgical resection Oncology medicine.medical_specialty Stromal cell Gastrointestinal Stromal Tumors Antineoplastic Agents Cochrane Library Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Internal medicine Humans Medicine 030212 general & internal medicine Progression-free survival Protein Kinase Inhibitors Aged Gastrointestinal Neoplasms Aged 80 and over business.industry Hazard ratio General Medicine Middle Aged Combined Modality Therapy Confidence interval Treatment Outcome 030220 oncology & carcinogenesis Meta-analysis Female Surgery Neoplasm Recurrence Local business Tyrosine kinase |
| Zdroj: | International Journal of Surgery. 56:108-114 |
| ISSN: | 1743-9191 |
| DOI: | 10.1016/j.ijsu.2018.06.016 |
| Popis: | Background The role of surgical resection for patients with recurrent or metastatic gastrointestinal stromal tumors is still controversial. This meta-analysis aims to investigate the clinical outcomes of surgery combined with tyrosine kinase inhibitors among patients with recurrent or metastatic gastrointestinal stromal tumors. Methods We systematically searched PubMed, EMBASE, the Cochrane Library and Wanfangdata without language restriction. Random effect models were used to estimate pooled hazard ratio and the corresponding 95% confidence intervals. Subgroup analyses, sensitivity analysis and trim and fill analysis were also performed. Results A total of 1416 patient from 9 studies were finally enrolled in this meta-analysis. The summary results showed that surgery combined with tyrosine kinase inhibitors showed a tendency of a longer overall survival compared with tyrosine kinase inhibitors treatment alone (HR by random-effects model 0.68, 95% CI 0.54–0.85, I2 = 44.7%) and improved progress-free survival (HR by random-effects model 0.50,95% CI, 0.33–0.76, I2 = 17.9%). The trim and fill analysis and sensitive analysis indicated the relatively robust result. Conclusion Surgery combined with tyrosine kinase inhibitors therapy is associated with a better overall survival and progression free survival for patients with recurrent or metastatic gastrointestinal stromal tumors as compared with TKIs treatment alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect